FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Nicholas Donato

Research Profile

Chemicals & Drugs

Disorders

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Anatomy

Physiology

Phenomena

Phosphorylation

Living Beings

Mouse

Co-author Network

Publications

TOP 3
Jeffrey W Perry; H D Hollis Showalter; Mohammad Ahmed; Kyeong-Ok Chang; Nicholas J Donato; Christiane E Wobus
Antiviral activity of a small molecule deubiquitinase inhibitor occurs via induction of the unfolded protein response.
Eliza Vakana; Heather Glaser; Nicholas J Donato; Jessica K Altman; Leonidas C Platanias
Antileukemic effects of AMPK activators on BCR-ABL-expressing cells.
Zhenghong Peng; Moshe Talpaz; Shimei Wang; Nicholas J Donato; Dongmei Han; Alexander Levitzki; David Maxwell; Ashutosh Pal; William Bornmann
Tyrphostin-like compounds with ubiquitin modulatory activity as possible therapeutic agents for multiple myeloma.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Nicholas Donato (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Jeffrey W Perry; H D Hollis Showalter; Mohammad Ahmed; Kyeong-Ok Chang; Nicholas J Donato; Christiane E Wobus
Antiviral activity of a small molecule deubiquitinase inhibitor occurs via induction of the unfolded protein response.
PLoS pathogens 2012;8(7):e1002783.
2011: Eliza Vakana; Heather Glaser; Nicholas J Donato; Jessica K Altman; Leonidas C Platanias
Antileukemic effects of AMPK activators on BCR-ABL-expressing cells.
Blood 2011;118(24):6399-402.
2011: Zhenghong Peng; Moshe Talpaz; Shimei Wang; Nicholas J Donato; Dongmei Han; Alexander Levitzki; David Maxwell; Ashutosh Pal; William Bornmann
Tyrphostin-like compounds with ubiquitin modulatory activity as possible therapeutic agents for multiple myeloma.
Bioorganic & medicinal chemistry 2011;19(23):7194-204.
2011: Kristin M Burkholder; Nicholas J Donato; Vaibhav Kapuria; Jeffrey W Perry; Hollis D Showalter; Christiane E Wobus; Mary O'Riordan
A small molecule deubiquitinase inhibitor increases localization of inducible nitric oxide synthase to the macrophage phagosome and enhances bacterial killing.
Infection and immunity 2011;79(12):4850-7.
2011: Vaibhav Kapuria; Alexander Levitzki; David Maxwell; Waldemar Priebe; H D Hollis Showalter; Roderick J Sorenson; Moshe Talpaz; William G Bornmann; Nicholas J Donato
A novel small molecule deubiquitinase inhibitor blocks Jak2 signaling through Jak2 ubiquitination.
Cellular signalling 2011;23(12):2076-85.
2011: Nicholas J Donato
Imatinib is receptive to a collaboration.
Blood 2011;118(15):4009-10.
2011: Nicholas J Donato
Bcr-Abl adds another twist to cell fate.
Blood 2011;118(10):2646-7.
2011: Vaibhav Kapuria; Paul D Kirchhoff; Luke Peterson; H D Hollis Showalter; Moshe Talpaz; Nicholas J Donato
Protein cross-linking as a novel mechanism of action of a ubiquitin-activating enzyme inhibitor with anti-tumor activity.
Biochemical pharmacology 2011;82(4):341-9.
2011: Marta Albajar; M Teresa Gómez-Casares; Javier Llorca; Itsaso Mauleon; Jose P Vaqué; Juan C Acosta; Arancha Bermúdez; Nicholas J Donato; M Dolores Delgado; Javier León
MYC in chronic myeloid leukemia: induction of aberrant DNA synthesis and association with poor response to imatinib.
Molecular cancer research : MCR 2011;9(5):564-76.
2011: Luke Peterson; E Mitrikeska; D Giannola; Y Lui; Haiying Sun; Dale Bixby; Sami Malek; Nicholas J Donato; Shaomeng Wang; Moshe Talpaz
p53 stabilization induces apoptosis in chronic myeloid leukemia blast crisis cells.
Leukemia 2011;25(5):761-9.
2011: Hanshi Sun; Vaibhav Kapuria; Luke Peterson; Dexing Fang; William G Bornmann; Geoffrey Bartholomeusz; Moshe Talpaz; Nicholas J Donato
Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis.
Blood 2011;117(11):3151-62.
2011: Nicholas J Donato; Luke Peterson
Chronic myeloid leukemia stem cells and developing therapies.
Leukemia & lymphoma 2011;52 Suppl 1():60-80.
2010: Vaibhav Kapuria; Luke Peterson; Dexing Fang; William G Bornmann; Moshe Talpaz; Nicholas J Donato
Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis.
Cancer research 2010;70(22):9265-76.
2010: Maria Rosa Lidonnici; Alessandra Audia; Angela Rachele Soliera; Marco Prisco; Giovanna Ferrari-Amorotti; Todd Waldron; Nicholas J Donato; Ying Zhang; Robert V Martinez; Tessa L Holyoake; Bruno Calabretta
Expression of the transcriptional repressor Gfi-1 is regulated by C/EBP{alpha} and is involved in its proliferation and colony formation-inhibitory effects in p210BCR/ABL-expressing cells.
Cancer research 2010;70(20):7949-59.
2010: Nathalie Carayol; Eliza Vakana; Antonella Sassano; Surinder Kaur; Dennis J Goussetis; Heather Glaser; Brian J Druker; Nicholas J Donato; Jessica K Altman; Sharon Barr; Leonidas C Platanias
Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells.
Proceedings of the National Academy of Sciences of the United States of America 2010;107(28):12469-74.
2010: J Wu; F Meng; Y Ying; Z Peng; L Daniels; W G Bornmann; A Quintás-Cardama; Diane Roulston; Moshe Talpaz; Luke Peterson; Nicholas J Donato
ON012380, a putative BCR-ABL kinase inhibitor with a unique mechanism of action in imatinib-resistant cells.
Leukemia 2010;24(4):869-72.
2010: Nicholas J Donato; Dexing Fang; Hanshi Sun; Diane Giannola; Luke Peterson; Moshe Talpaz
Targets and effectors of the cellular response to aurora kinase inhibitor MK-0457 (VX-680) in imatinib sensitive and resistant chronic myelogenous leukemia.
Biochemical pharmacology 2010;79(5):688-97.
2009: Cristian Bellodi; Maria Rosa Lidonnici; Ashley Hamilton; G Vignir Helgason; Angela Rachele Soliera; Mattia Ronchetti; Sara Galavotti; Kenneth W Young; Tommaso Selmi; Rinat Yacobi; Richard A Van Etten; Nicholas J Donato; Ann Hunter; David Dinsdale; Elena Tirrò; Paolo Vigneri; Pierluigi Nicotera; Martin J Dyer; Tessa Holyoake; Paolo Salomoni; Bruno Calabretta
Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells.
The Journal of clinical investigation 2009;119(5):1109-23.
2008: T Pene-Dumitrescu; Luke Peterson; Nicholas J Donato; Thomas E Smithgall
An inhibitor-resistant mutant of Hck protects CML cells against the antiproliferative and apoptotic effects of the broad-spectrum Src family kinase inhibitor A-419259.
Oncogene 2008;27(56):7055-69.
2008: Angela Rachele Soliera; Maria Rosa Lidonnici; Giovanna Ferrari-Amorotti; Marco Prisco; Ying Zhang; Robert V Martinez; Nicholas J Donato; Bruno Calabretta
Transcriptional repression of c-Myb and GATA-2 is involved in the biologic effects of C/EBPalpha in p210BCR/ABL-expressing cells.
Blood 2008;112(5):1942-50.
2008: Ji Wu; Feng Meng; Ling-Yuan Kong; Zhenghong Peng; Yunming Ying; William G Bornmann; Bryant G Darnay; Betty Lamothe; Hanshi Sun; Moshe Talpaz; Nicholas J Donato
Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.
Journal of the National Cancer Institute 2008;100(13):926-39.
2008: A Quintás-Cardama; D L Gibbons; H Kantarjian; Moshe Talpaz; Nicholas J Donato; J Cortes
Sequencing of subcloned PCR products facilitates earlier detection of BCR-ABL1(T315I) and other mutants compared to direct sequencing of the ABL1 kinase domain.
Leukemia 2008;22(4):885-8.
2008: Ji Wu; Feng Meng; Henry Lu; Ling Kong; William G Bornmann; Zhenghong Peng; Moshe Talpaz; Nicholas J Donato
Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells.
Blood 2008;111(7):3821-9.
2007: Faye M Johnson; Babita Saigal; Hai Tran; Nicholas J Donato
Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(14):4233-44.
2007: T Mughal; J Cortes; Nicholas C P Cross; Nicholas J Donato; O Hantschel; E Jabbour; H Kantarjian; J V Melo; Tomasz Skorski; R T Silver; J M Goldman
Chronic myeloid leukemia--some topical issues.
Leukemia 2007;21(7):1347-52.
2007: Ralph G Zinner; John Nemunaitis; Irene A Eiseman; Hyung Ju C Shin; Stephen C Olson; James Christensen; Xin Huang; Peter F Lenehan; Nicholas J Donato; Dong M Shin
Phase I clinical and pharmacodynamic evaluation of oral CI-1033 in patients with refractory cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(10):3006-14.
2007: Geoffrey Bartholomeusz; Moshe Talpaz; William G Bornmann; Ling-Yuan Kong; Nicholas J Donato
Degrasyn activates proteasomal-dependent degradation of c-Myc.
Cancer research 2007;67(8):3912-8.
2007: Geoffrey Bartholomeusz; Moshe Talpaz; Vaibhav Kapuria; Ling-Yuan Kong; Shimei Wang; Zeev Estrov; Waldemar Priebe; Ji Wu; Nicholas J Donato
Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells.
Blood 2007;109(8):3470-8.
2006: Giovanna Ferrari-Amorotti; Karen Keeshan; Michela Zattoni; Clara Guerzoni; Giorgio Iotti; Sara Cattelani; Nicholas J Donato; Bruno Calabretta
Leukemogenesis induced by wild-type and STI571-resistant BCR/ABL is potently suppressed by C/EBPalpha.
Blood 2006;108(4):1353-62.
2006: Moshe Talpaz; Neil P Shah; Andrew Lamb; Nicholas J Donato; John Nicoll; Ronald L Paquette; Jorge Cortes; Susan O'Brien; Claude Nicaise; Eric Bleickardt; M Anne Blackwood-Chirchir; Vishwanath Iyer; Tai-Tsang Chen; Fei Huang; Arthur P DeCillis; Charles L Sawyers
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
The New England journal of medicine 2006;354(24):2531-41.
2006: Jim Klostergaard; ME Leroux; Edmond Auzenne; M Khodadadian; WC Spohn; J Y Wu; Nicholas J Donato
Hyperthermia engages the intrinsic apoptotic pathway by enhancing upstream caspase activation to overcome apoptotic resistance in MCF-7 breast adenocarcinoma cells.
Journal of cellular biochemistry 2006;98(2):356-69.
2006: Joya Chandra; Jeannette Tracy; David Loegering; Karen Flatten; Srdan Verstovsek; Miloslav Beran; Mercedes Gorre; Zeev Estrov; Nicholas J Donato; Moshe Talpaz; Charles L Sawyers; Kapil N Bhalla; Judith E Karp; Edward A Sausville; Scott H Kaufmann
Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance.
Blood 2006;107(6):2501-6.
2006: Jose G Trevino; Justin M Summy; Donald P Lesslie; Nila U Parikh; David S Hong; Francis Y Lee; Nicholas J Donato; James L Abbruzzese; Cheryl H Baker; Gary E Gallick
Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model.
The American journal of pathology 2006;168(3):962-72.
2005: H Gao; Bang-Ning Lee; Moshe Talpaz; Nicholas J Donato; Jorge E Cortes; Hagop M Kantarjian; James M Reuben
Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia.
Leukemia 2005;19(11):1905-11.
2005: Faye M Johnson; Babita Saigal; Nicholas J Donato
Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells.
Journal of cellular physiology 2005;205(2):218-27.
2005: Faye M Johnson; Babita Saigal; Moshe Talpaz; Nicholas J Donato
Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(19 Pt 1):6924-32.
2004: Faye M Johnson; Peiying Yang; Robert A Newman; Nicholas J Donato
Cyclooxygenase-2 induction and prostaglandin E2 accumulation in squamous cell carcinoma as a consequence of epidermal growth factor receptor activation by imatinib mesylate.
Journal of experimental therapeutics & oncology 2004;4(4):317-25.
2004: Nicholas J Donato; Jim Klostergaard
Distinct stress and cell destruction pathways are engaged by TNF and ceramide during apoptosis of MCF-7 cells.
Experimental cell research 2004;294(2):523-33.
2004: Nicholas J Donato; Ji Y Wu; Jonathan Stapley; Hui Lin; Ralph B Arlinghaus; Bharat B Aggarwal; Shishir Shishodia; Maher Albitar; Kimberly Hayes; Andrew Lamb; Moshe Talpaz; Shishir Shishodin
Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia.
Cancer research 2004;64(2):672-7.
2003: Alok C Bharti; Nicholas J Donato; Bharat B Aggarwal
Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells.
Journal of immunology (Baltimore, Md. : 1950) 2003;171(7):3863-71.
2003: Alok C Bharti; Nicholas J Donato; Sujay Singh; Bharat B Aggarwal
Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis.
Blood 2003;101(3):1053-62.
2003: Nicholas J Donato; Ji Yuan Wu; Jonathan Stapley; Gary E Gallick; Hui Lin; Ralph B Arlinghaus; Moshe Talpaz
BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.
Blood 2003;101(2):690-8.
2002: Edmond Auzenne; Nicholas J Donato; Chun Li; Elena Leroux; Roger E Price; David Farquhar; Jim Klostergaard
Superior therapeutic profile of poly-L-glutamic acid-paclitaxel copolymer compared with taxol in xenogeneic compartmental models of human ovarian carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(2):573-81.
2001: Yi-He Ling; Nicholas J Donato; Roman Perez-Soler
Sensitivity to topoisomerase I inhibitors and cisplatin is associated with epidermal growth factor receptor expression in human cervical squamous carcinoma ME180 sublines.
Cancer chemotherapy and pharmacology 2001;47(6):473-80.
2001: S A Beresford; Michael A Davies; Gary E Gallick; Nicholas J Donato
Differential effects of phosphatidylinositol-3/Akt-kinase inhibition on apoptotic sensitization to cytokines in LNCaP and PCc-3 prostate cancer cells.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2001;21(5):313-22.
2001: Dong M Shin; Nicholas J Donato; Roman Perez-Soler; Hyung Ju C Shin; J Y Wu; P Zhang; KN Lawhorn; Fadlo R Khuri; Bonnie S Glisson; J Myers; Gary L Clayman; David G Pfister; J Falcey; Harlan W Waksal; John Mendelsohn; Waun Ki Hong
Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(5):1204-13.
2001: Nicholas J Donato; J Y Wu; Ling Zhang; Andrew Lamb; Moshe Talpaz
Down-regulation of interleukin-3/granulocyte-macrophage colony-stimulating factor receptor beta-chain in BCR-ABL(+) human leukemic cells: association with loss of cytokine-mediated Stat-5 activation and protection from apoptosis after BCR-ABL inhibition.
Blood 2001;97(9):2846-53.
2001: Elena Leroux; Edmond Auzenne; Douglas Weidner; Z Y Wu; Nicholas J Donato; Jim Klostergaard
Febrile and acute hyperthermia enhance TNF-induced necrosis of murine L929 fibrosarcoma cells via caspase-regulated production of reactive oxygen intermediates.
Journal of cellular physiology 2001;187(2):256-63.
2000: Nicholas J Donato; Moshe Talpaz
Clinical use of tyrosine kinase inhibitors: therapy for chronic myelogenous leukemia and other cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(8):2965-6.
2000: Nicholas J Donato; M Perez; H Kang; Zahid H Siddik; Yi-He Ling; Roman Perez-Soler
EGF receptor and p21WAF1 expression are reciprocally altered as ME-180 cervical carcinoma cells progress from high to low cisplatin sensitivity.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(1):193-202.
1999: R K Doman; M Perez; Nicholas J Donato
JNK and p53 stress signaling cascades are altered in MCF-7 cells resistant to tumor necrosis factor-mediated apoptosis.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 1999;19(3):261-9.
1999: M Perez; B Haschke; Nicholas J Donato
Differential expression and translocation of protein tyrosine phosphatase 1B-related proteins in ME-180 tumor cells expressing apoptotic sensitivity and resistance to tumor necrosis factor: potential interaction with epidermal growth factor receptor.
Oncogene 1999;18(4):967-78.
1998: Nicholas J Donato; M Perez
Tumor necrosis factor-induced apoptosis stimulates p53 accumulation and p21WAF1 proteolysis in ME-180 cells.
The Journal of biological chemistry 1998;273(9):5067-72.
1996: Nicholas J Donato; C A Martin; M Perez; Robert A Newman; J C Vidal; M Etcheverry
Regulation of epidermal growth factor receptor activity by crotoxin, a snake venom phospholipase A2 toxin. A novel growth inhibitory mechanism.
Biochemical pharmacology 1996;51(11):1535-43.
1996: M Perez; Nicholas J Donato
Activation of epidermal growth factor receptor tyrosine phosphorylation by tumor necrosis factor correlates with loss of cytotoxic activity.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 1996;16(4):307-14.
1996: Michael G Rosenblum; L Cheung; S K Kim; K Mujoo; Nicholas J Donato; James L Murray
Cellular resistance to the antimelanoma immunotoxin ZME-gelonin and strategies to target resistant cells.
Cancer immunology, immunotherapy : CII 1996;42(2):115-21.
1994: Roman Perez-Soler; Nicholas J Donato; Dong M Shin; Michael G Rosenblum; Hua-Zhong Zhang; C Tornos; H Brewer; J C Chan; Jin S Lee; Waun Ki Hong
Tumor epidermal growth factor receptor studies in patients with non-small-cell lung cancer or head and neck cancer treated with monoclonal antibody RG 83852.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(4):730-9.
1994: K Nishikawa; J Rotbein; D Vijjeswarapu; Laurie B Owen-Schaub; Michael G Rosenblum; Nicholas J Donato
Positive and negative selection for tumor necrosis factor responsiveness reveals an inhibitory role for EGF receptor in TNF-induced antiproliferation.
Lymphokine and cytokine research 1994;13(1):37-45.
1993: Nicholas J Donato; Duen-Hwa Yan; Mien-Chie Hung; Michael G Rosenblum
Epidermal growth factor receptor expression and function control cytotoxic responsiveness to tumor necrosis factor in ME-180 squamous carcinoma cells.
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1993;4(5):411-9.
1993: K Mujoo; Nicholas J Donato; Ruth Lapushin; Michael G Rosenblum; James L Murray
Tumor necrosis factor alpha and gamma-interferon enhancement of anti-epidermal growth factor receptor monoclonal antibody binding to human melanoma cells.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1993;13(3):166-74.
1992: K Nishikawa; Michael G Rosenblum; Robert A Newman; Tej K Pandita; Walter N Hittelman; Nicholas J Donato
Resistance of human cervical carcinoma cells to tumor necrosis factor correlates with their increased sensitivity to cisplatin: evidence of a role for DNA repair and epidermal growth factor receptor.
Cancer research 1992;52(17):4758-65.
1992: Nicholas J Donato; Michael G Rosenblum; PA Steck
Tumor necrosis factor regulates tyrosine phosphorylation on epidermal growth factor receptors in A431 carcinoma cells: evidence for a distinct mechanism.
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1992;3(5):259-68.
1991: Nicholas J Donato; J Rotbein; Michael G Rosenblum
Tumor necrosis factor stimulates ornithine decarboxylase activity in human fibroblasts and tumor target cells.
Journal of cellular biochemistry 1991;46(1):69-77.
1989: Nicholas J Donato; Gary E Gallick; PA Steck; Michael G Rosenblum
Tumor necrosis factor modulates epidermal growth factor receptor phosphorylation and kinase activity in human tumor cells. Correlation with cytotoxicity.
The Journal of biological chemistry 1989;264(34):20474-81.
1989: Nicholas J Donato; C Ince; Michael G Rosenblum; Gary E Gallick
Early events in the antiproliferative action of tumor necrosis factor are similar to the early events in epidermal growth factor growth stimulation.
Journal of cellular biochemistry 1989;41(3):139-57.
1989: Michael G Rosenblum; Nicholas J Donato
Tumor necrosis factor alpha: a multifaceted peptide hormone.
Critical reviews in immunology 1989;9(1):21-44.
1988: Michael G Rosenblum; Nicholas J Donato; Jordan U Gutterman
Characterization of human recombinant tumor necrosis factor-alpha antiproliferative effects on human cells in culture.
Lymphokine research 1988;7(2):107-17.
1986: Nicholas J Donato; Carl Ware; Craig V Byus
A rat monoclonal antibody which interacts with mammalian ornithine decarboxylase at an epitope involved in phosphorylation.
Biochimica et biophysica acta 1986;884(2):370-82.
1985: Carl Ware; Nicholas J Donato; K Dorshkind
Human, rat or mouse hybridomas secrete high levels of monoclonal antibodies following transplantation into mice with severe combined immunodeficiency disease (SCID).
Journal of immunological methods 1985;85(2):353-61.
1981: V S Wu; Nicholas J Donato; Craig V Byus
Growth state-dependent alterations in the ability of 12-O-tetradecanoylphorbol-13-acetate to increase ornithine decarboxylase activity in Reuber h35 Hepatoma cells.
Cancer research 1981;41(9 Pt 1):3384-91.